Search

Your search keyword '"MESH: Astrocytoma"' showing total 13 results
Start Over Descriptor "MESH: Astrocytoma" Topic medicine
13 results on '"MESH: Astrocytoma"'

1. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas

Author

Pierre Verrelle, Nathalie Grandin, Bruno Pereira, Ahmed Idbaih, Delphine Poncet, François Ducray, Franck Bielle, Pauline Billard, Patrick Lomonte, Jean-Yves Delattre, Dominique Figarella-Branger, Marc Sanson, Caroline Dehais, Catherine Carpentier, Camille Cohen, Michel Charbonneau, Génétique, Reproduction et Développement (GReD), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Clermont-Ferrand, Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Université de Caen Normandie (UNICAEN), Normandie Université (NU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de génétique et de physiologie moléculaire et cellulaire (CGPhiMC), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Cancer Resistance Exploring and Targeting (CREaT), Université d'Auvergne - Clermont-Ferrand I (UdA), Institut Armand Frappier (INRS-IAF), Institut National de la Recherche Scientifique [Québec] (INRS)-Réseau International des Instituts Pasteur (RIIP), Pola Network, Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Institut NeuroMyoGène (INMG), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Charles Foix [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), Chimie, Modélisation et Imagerie pour la Biologie [Orsay], Université Paris-Sud - Paris 11 (UP11)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université - Département de neurologie 2 - Mazarin, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Réseau International des Instituts Pasteur (RIIP)-Institut National de la Recherche Scientifique [Québec] (INRS), and LOMONTE, PATRICK

Subjects
Male, Telomerase, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV]Life Sciences [q-bio], [SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC], lcsh:RC346-429, MESH: Isocitrate Dehydrogenase, Cohort Studies, 0302 clinical medicine, ATRX loss of expression, Medicine, MESH: Cohort Studies, ComputingMilieux_MISCELLANEOUS, MESH: Aged, 0303 health sciences, MESH: Middle Aged, MESH: X-linked Nuclear Protein, Brain Neoplasms, MESH: Gene Expression Regulation, Neoplastic, Middle Aged, Isocitrate Dehydrogenase, 3. Good health, Gene Expression Regulation, Neoplastic, Secondary glioblastoma, 030220 oncology & carcinogenesis, MESH: Brain Neoplasms, [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Female, Anaplastic astrocytoma, Adult, X-linked Nuclear Protein, IDH1, MESH: Mutation, [SDV.CAN]Life Sciences [q-bio]/Cancer, Neuropathology, Astrocytoma, Pathology and Forensic Medicine, MESH: Telomere Homeostasis, 03 medical and health sciences, Cellular and Molecular Neuroscience, [SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Alternative lengthening of telomeres, Humans, lcsh:Neurology. Diseases of the nervous system, ATRX, Aged, 030304 developmental biology, IDH1/2 mutations, MESH: Humans, business.industry, Research, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Telomere Homeostasis, Cancer, MESH: Adult, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, medicine.disease, MESH: Male, Telomere, MESH: Astrocytoma, Mutation, Cancer cell, Cancer research, Neurology (clinical), business, MESH: Female
Abstract

All cancer cells need to maintain functional telomeres to sustain continuous cell division and proliferation. In human diffuse gliomas, functional telomeres are maintained due either to reactivation of telomerase expression, the main pathway in most cancer types, or to activation of a mechanism called the alternative lengthening of telomeres (ALT). The presence of IDH1/2 mutations (IDH-mutant) together with loss of ATRX expression (ATRX-lost) are frequently associated with ALT in diffuse gliomas. However, detection of ALT, anda fortioriits quantification, are rarely, if ever, measured in neuropathology laboratories. We measured the level of ALT activity using the previously described quantitative “C-circle” assay and analyzed it in a well characterized cohort of 104 IDH-mutant and ATRX-lost adult diffuse gliomas. We report that in IDH-mutant ATRX-lost anaplastic astrocytomas, the intensity of ALT was inversely correlated with age (p

Published
2019
Full Text
View/download PDF

2. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging

Author

Jean-Pierre Bourgeois, Anne-Marie Le Sourd, Fabienne Glacial, Pierre Lafaye, Susanna Celli, Pierre-Olivier Couraud, Babette B. Weksler, Ignacio A. Romero, Tengfei Li, Salah Mecheri, François Rougeon, Production de Protéines Recombinantes et d'Anticorps (Plate-Forme), Institut Pasteur [Paris] (IP), Gènes, Synapses et Cognition (CNRS - UMR3571 ), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Biologie des Interactions Hôte-Parasite, Division of Hematology and Oncology, Weill Medical College of Cornell University [New York], Department of Life, Health and Chemical Sciences, The Open University [Milton Keynes] (OU), Génétique et Biochimie du Développement, Institut Pasteur [Paris], Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Gènes, Synapses et Cognition, Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ), Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Cochin ( UM3 (UMR 8104 / U1016) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), and The Open University [Milton Keynes] ( OU )

Subjects
MESH : Cell Line, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Plasmodium berghei, MESH : Immunohistochemistry, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Fluorescent Antibody Technique, Biochemistry, law.invention, Green fluorescent protein, MESH : Blood-Brain Barrier, MESH: Blood-Brain Barrier, Mice, 0302 clinical medicine, law, MESH: Glial Fibrillary Acidic Protein, MESH : Female, MESH: Animals, MESH: Fluorescent Antibody Technique, [ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/Imaging, 0303 health sciences, biology, Glial fibrillary acidic protein, intrabodies, MESH: Enzyme-Linked Immunosorbent Assay, Brain, MESH : Enzyme-Linked Immunosorbent Assay, MESH : Glial Fibrillary Acidic Protein, Immunohistochemistry, nanobodies, MESH : Mutagenesis, Site-Directed, 3. Good health, MESH: Mutagenesis, Site-Directed, medicine.anatomical_structure, Blood-Brain Barrier, [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, MESH : Single-Domain Antibodies, Recombinant DNA, Female, Antibody, Biotechnology, MESH: Cell Line, Tumor, MESH : Recombinant Fusion Proteins, Recombinant Fusion Proteins, [ SDV.IMM.IMM ] Life Sciences [q-bio]/Immunology/Immunotherapy, fluobodies, Enzyme-Linked Immunosorbent Assay, MESH : Mice, Inbred C57BL, Astrocytoma, Blood–brain barrier, MESH: Single-Domain Antibodies, camelids, Cell Line, 03 medical and health sciences, MESH: Brain, Antigen, MESH: Mice, Inbred C57BL, Cell Line, Tumor, MESH : Mice, Glial Fibrillary Acidic Protein, Genetics, medicine, MESH: Recombinant Fusion Proteins, MESH: Plasmodium berghei, Animals, Humans, Molecular Biology, MESH: Mice, MESH : Plasmodium berghei, 030304 developmental biology, MESH: Humans, MESH : Cell Line, Tumor, MESH : Humans, MESH : Astrocytes, MESH : Astrocytoma, MESH: Immunohistochemistry, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Single-Domain Antibodies, central nervous system, Fusion protein, Molecular biology, MESH: Cell Line, MESH: Astrocytes, Mice, Inbred C57BL, MESH : Fluorescent Antibody Technique, MESH: Astrocytoma, MESH : Brain, Astrocytes, biology.protein, Mutagenesis, Site-Directed, Paratope, MESH : Animals, BBB, MESH: Female, 030217 neurology & neurosurgery
Abstract

International audience; Antibodies normally do not cross the blood-brain barrier (BBB) and cannot bind an intracellular cerebral antigen. We demonstrate here for the first time that a new class of antibodies can cross the BBB without treatment. Camelids produce native homodimeric heavy-chain antibodies, the paratope being composed of a single-variable domain called VHH. Here, we used recombinant VHH directed against human glial fibrillary acidic protein (GFAP), a specific marker of astrocytes. Only basic VHHs (e.g., pI=9.4) were able to cross the BBB in vitro (7.8 vs. 0% for VHH with pI=7.7). By intracarotid and intravenous injections into live mice, we showed that these basic VHHs are able to cross the BBB in vivo, diffuse into the brain tissue, penetrate into astrocytes, and specifically label GFAP. To analyze their ability to be used as a specific transporter, we then expressed a recombinant fusion protein VHH-green fluorescent protein (GFP). These "fluobodies" specifically labeled GFAP on murine brain sections, and a basic variant (pI=9.3) of the fusion protein VHH-GFP was able to cross the BBB and to label astrocytes in vivo. The potential of VHHs as diagnostic or therapeutic agents in the central nervous system now deserves attention.

Published
2012
Full Text
View/download PDF

3. A fraction of neurofibromin interacts with PML bodies in the nucleus of the CCF astrocytoma cell line

Author

Michel Doudeau, Séverine Morisset-Lopez, Hélène Bénédetti, Béatrice Vallée, Sandrine Villette, Tobias Hévor, Chantal Pichon, Fabienne Godin, Maryvonne Ardourel, Centre de biophysique moléculaire (CBM), Université d'Orléans (UO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Laboratoire de Neurobiologie, and Université d'Orléans (UO)

Subjects
PROTEIN, Proximity ligation assay, PLA technique, Biochemistry, Immunolocalization, PATHWAY, 0302 clinical medicine, GENE-PRODUCT, 0303 health sciences, Neurofibromin 1, biology, MESH: Neurofibromin 1, medicine.anatomical_structure, DIFFERENTIATION, INACTIVATION, MESH: Cell Nucleus, congenital, hereditary, and neonatal diseases and abnormalities, MESH: Cell Line, Tumor, HETEROZYGOSITY, Biophysics, Astrocytoma, Nucleus, Gene product, 03 medical and health sciences, Nf1, Cell Line, Tumor, medicine, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, Molecular Biology, neoplasms, Actin, TYPE-1, 030304 developmental biology, Cell Nucleus, MESH: Humans, ADENYLYL-CYCLASE, Cell Biology, MESH: Multiprotein Complexes, Actin cytoskeleton, Molecular biology, eye diseases, nervous system diseases, MESH: Astrocytes, PML bodies, GAP-RELATED DOMAIN, MESH: Astrocytoma, Cytoplasm, Astrocytes, Multiprotein Complexes, biology.protein, NF1 TUMOR-SUPPRESSOR, 030217 neurology & neurosurgery, Nuclear localization sequence
Abstract

International audience; Neurofibromatosis type 1 is a common genetic disease that causes nervous system tumors, and cognitive deficits. It is due to mutations within the NF1 gene, which encodes the Nf1 protein. Nf1 has been shown to be involved in the regulation of Ras, cAMP and actin cytoskeleton dynamics. In this study, using immunofluorescence experiments, we have shown a partial nuclear localization of Nf1 in the astrocytoma cell line: CCF and we have demonstrated that Nf1 partially colocalizes with PML (promyelocytic leukemia) nuclear bodies. A direct interaction between Nf1 and the multiprotein complex has further been demonstrated using "in situ" proximity ligation assay (PLA).

Published
2012
Full Text
View/download PDF

4. Opposing roles of connexin43 in glioma progression

Author

Sophie Crespin, Wun Chey Sin, Marc Mesnil, Department of Cellular and Physiological Sciences, University of British Columbia (UBC), laboratory of clinical investigation III, University of Geneva [Switzerland], Institut de physiologie et biologie cellulaires (IPBC), and Université de Poitiers-Centre National de la Recherche Scientifique (CNRS)

Subjects
Central Nervous System, [SDV]Life Sciences [q-bio], Cell, Apoptosis, Biochemistry, MESH: Glioma, Cell growth, Mice, 0302 clinical medicine, Cell Movement, Homeostasis, MESH: Animals, MESH: Cell Movement, Migration, Regulation of gene expression, 0303 health sciences, Brain Neoplasms, Cell migration, Gap junctional intercellular communication, MESH: Gene Expression Regulation, Neoplastic, Glioma, Cell biology, Gene Expression Regulation, Neoplastic, medicine.anatomical_structure, MESH: Homeostasis, 030220 oncology & carcinogenesis, MESH: Brain Neoplasms, cardiovascular system, Disease Progression, MESH: Disease Progression, biological phenomena, cell phenomena, and immunity, Biophysics, Biology, Astrocytoma, Models, Biological, 03 medical and health sciences, Paracrine signalling, MESH: Cell Proliferation, medicine, Connexin43, MESH: Central Nervous System, Animals, Humans, Transcription factor, MESH: Mice, 030304 developmental biology, Cell Proliferation, MESH: Humans, MESH: Apoptosis, Cell Membrane, MESH: Models, Biological, Cell Biology, medicine.disease, Actin cytoskeleton, MESH: Connexin 43, MESH: Astrocytoma, Connexin 43, sense organs, MESH: Cell Membrane
Abstract

International audience; Despite the tremendous amount of data over the last 40years, lack of gap junctional intercellular communication (GJIC) or altered expression of gap junction proteins is still a lesser known 'hallmark' of cancer. Expression of astrocytic gap junction protein, connexin43 (Cx43), is often reduced in astrocytomas, the most common neoplasia of the central nervous system (CNS) in adults. Supported by a number of evidences, the global decrease of Cx43 expression appears to be advantageous for the growth of glioma cells. Although the mechanisms by which Cx43 regulates the expression levels of proteins involved in cell growth is unclear, there are evidences to suggest that it might be independent of their channel forming properties. In this regard, the carboxyl tail of Cx43 may have the ability to control the translocation of transcription factor regulators into the nucleus. However, this putative tumor suppressor effect of Cx43 is counterbalanced by its capacity to enhance the migration of glioma cells out of the tumor core through mechanisms that seems to implicate its carboxyl tail, possibly by interacting with the actin cytoskeleton. This ambivalence between the tumor suppressor effect and promotion of cell migration may partly be explained by the heterogeneous expression of Cx43 in the glioma core especially at the malignant glioblastoma stage; some tumor cells would be expected to migrate (Cx43 expressing cells) and others to proliferate (non-expressing Cx43 cells). Moreover, the involvement of Cx43 in glioma progression seems to be more complex since, in addition, GJIC may increase their resistance to apoptosis and Cx43 may also affect cell homeostasis in a paracrine fashion via hemichannel action. In conclusion, Cx43 appears to be involved at different levels of the glioma progression by acting on cell growth regulation, promotion of cell migration and resistance to apoptosis. This article is part of a Special Issue entitled: The Communicating junctions, composition, structure and characteristics.

Published
2011
Full Text
View/download PDF

5. Dynamic susceptibility contrast-enhanced MRI evaluation of cerebral intraventricular tumors: preliminary results

Author

J.F. Le Bas, S. Boini, Sylvie Grand, Jean-Louis Dietemann, A. Holveck, S. Bracard, Stéphane Kremer, M. Kirchin, Service de Neuro-Radiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Neuro-imagerie fonctionnelle et métabolique (ANTE-INSERM U836, équipe 5), Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique - Epidemiologie Clinique/essais Cliniques Nancy, Cancéropôle du Grand Est-Institut National de la Santé et de la Recherche Médicale (INSERM), Bracco Laboratory, ANTE-INSERM U836, équipe 6, Rayonnement synchrotron et recherche médicale, Unité d'Imagerie par Résonance Magnétique, CHU Grenoble-CHU Grenoble, Service de radiologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], and Dojat, Michel

Subjects
tumors, Male, perfusion imaging, Contrast Media, Perfusion scanning, Intraventricular tumor, MESH: Meningioma, 030218 nuclear medicine & medical imaging, MESH: Magnetic Resonance Imaging, 0302 clinical medicine, MESH: Cerebral Ventricle Neoplasms, Image Processing, Computer-Assisted, Medicine, Neurocytoma, intraventricular, MESH: Middle Aged, Radiological and Ultrasound Technology, medicine.diagnostic_test, imaging, MESH: Ependymoma, Middle Aged, MESH: Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Ependymoma, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Female, Radiology, Meningioma, Perfusion, Adult, medicine.medical_specialty, Astrocytoma, magnetic resonance, 03 medical and health sciences, MESH: Contrast Media, Subependymal zone, Humans, Radiology, Nuclear Medicine and imaging, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], [SDV.IB] Life Sciences [q-bio]/Bioengineering, MESH: Humans, Papilloma, business.industry, Dynamic Susceptibility Contrast-Enhanced MRI, Magnetic resonance imaging, MESH: Adult, MESH: Male, MESH: Astrocytoma, MESH: Neurocytoma, Giant cell, Neurology (clinical), Differential diagnosis, MESH: Papilloma, business, MESH: Female, Cerebral Ventricle Neoplasms, 030217 neurology & neurosurgery
Abstract

International audience; INTRODUCTION: The aims of the present study were to determine the perfusion characteristics of several types of intraventricular tumors and to evaluate the usefulness of dynamic contrast-enhanced MRI in making the differential diagnosis. METHODS: A total of 28 patients with intraventricular tumors (five meningiomas, five papillomas, three ependymomas, four subependymomas, seven central neurocytomas, two subependymal giant cell astrocytomas and two metastases) underwent conventional and dynamic susceptibility contrast-enhanced MRI. Cerebral blood volume (CBV) maps were obtained and the relative CBV (rCBV) calculated for each tumor. Mean rCBV(max) values were compared across the different types of tumors (ANOVA, P=0.05). RESULTS: Intraventricular tumors presented with three different patterns of vascularization: highly vascularized tumors (mean rCBV(max)>3), including papillomas, meningiomas and renal carcinoma metastases; poorly vascularized tumors (mean rCBV(max)2 but

Published
2009
Full Text
View/download PDF

6. Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection

Author

Luc Bauchet, Luc Taillandier, Philippe Peruzzi, Johan Pallud, Jacques Guyotat, Denys Fontaine, Marie-Hélène Baron, Emmanuel Mandonnet, Valérie Bernier, Laurent Capelle, Hugues Duffau, Réseau d'Etude des Gliomes, REG, Laboratoire d'Imagerie Fonctionnelle (LIF), Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR14-IFR49-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurochirurgie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Neurochirurgie, Centre Hospitalier Universitaire de Nice (CHU Nice), Service de Neuro-Oncologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de neuro-radiologie, CHU Grenoble, Université de Reims Champagne-Ardenne (URCA), Service de neurochirurgie, Hospices Civils de Lyon (HCL), Centre Alexis Vautrin (CAV), Service de radiothérapie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire d'Imagerie Fonctionnelle ( LIF ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -IFR14-IFR49-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], CHU Nice, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Université de Reims Champagne-Ardenne ( URCA ), Hospices Civils de Lyon ( HCL ), Centre Alexis Vautrin ( CAV ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO)

Subjects
Male, MESH : Oligodendroglioma, MESH : Retrospective Studies, Databases, Factual, MESH: Antineoplastic Agents, Alkylating, Neurosurgical Procedures, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Linear Models, MESH: Magnetic Resonance Imaging, MESH: Glioma, 0302 clinical medicine, MESH : Child, MESH : Linear Models, MESH: Child, Medicine, Statistical analysis, MESH : Female, 10. No inequality, Child, MESH: Middle Aged, MESH : Neoplasm Recurrence, Local, MESH: Kinetics, Brain Neoplasms, General Medicine, MESH: Follow-Up Studies, Glioma, MESH : Adult, MESH : Neurosurgical Procedures, Middle Aged, Magnetic Resonance Imaging, 3. Good health, Dacarbazine, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Brain Neoplasms, Disease Progression, MESH: Disease Progression, Female, Neurosurgery, MESH : Kinetics, MESH: Neoplasm Recurrence, Local, Surgical resection, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Antineoplastic Agents, Alkylating, Oligodendroglioma, MESH : Young Adult, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Databases, Factual, Astrocytoma, MESH: Dacarbazine, 03 medical and health sciences, Young Adult, MESH : Adolescent, MESH : Magnetic Resonance Imaging, Linear regression, Grade II Glioma, Temozolomide, Humans, MESH : Middle Aged, MESH : Brain Neoplasms, MESH : Dacarbazine, MESH: Oligodendroglioma, Antineoplastic Agents, Alkylating, Retrospective Studies, Mean diameter, MESH: Adolescent, MESH: Humans, business.industry, WHO Grade II Glioma, MESH : Humans, MESH : Follow-Up Studies, MESH : Astrocytoma, MESH: Adult, MESH: Neurosurgical Procedures, MESH: Retrospective Studies, MESH : Disease Progression, MESH: Databases, Factual, MESH: Male, Surgery, Kinetics, MESH: Astrocytoma, MESH : Glioma, Linear Models, National database, Neurology (clinical), Neoplasm Recurrence, Local, Nuclear medicine, business, MESH: Female, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract

International audience; Grade II gliomas grow slowly and linearly (at rates about 4 mm/year) before undergoing anaplastic transformation. In order to analyze how surgery may affect radiological grade II glioma kinetics, we restrospectively reviewed our national database searching for patients operated on for a supratentorial grade II glioma between 1997 and 2007. We selected patients with at least two postoperative MRI with a minimal delay of 6 months. For each patient, postoperative residues were segmented on successive MRIs. Velocities of diameter expansion were estimated by linear regression of mean diameter evolution for each patient. Fifty-four patients fulfilled inclusion criteria. Median postoperative follow-up was 1.6 years with, on average, 3.4 MRI examinations per patient. Postoperative growth rates of mean diameter were normally distributed, around a mean value of 4.3 mm/year (SD = 3.2 mm/year). Statistical analysis showed no difference between this distribution and the distribution of preoperative growth rates in a previous series of 143 grade II gliomas. For a subset of 23 patients, delay between first MRI and surgery made it possible to estimate also preoperative growth rates. Intrapatient comparison revealed that growth rates were grossly unchanged for 80% of cases. In summary, inter- and intrapatient comparison of pre- and postoperative growth rates proves that surgery does not change grade II glioma dynamics, thus, acting as a cytoreduction.

Published
2009
Full Text
View/download PDF

7. ATAD 3A and ATAD 3B are distal 1p-located genes differentially expressed in human glioma cell lines and present in vitro anti-oncogenic and chemoresistant properties

Author

Arnaud Hubstenberger, Jacques Baudier, Denis Rousseau, Gérard Labourdette, Transduction du Signal : Signalisation Calcique et Phosphorylation, Université Joseph Fourier - Grenoble 1 (UJF)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Neurochimie, Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), and Baudier, Jacques

Subjects
MESH: Protein Isoforms, medicine.disease_cause, Loss of heterozygosity, Mice, 0302 clinical medicine, Chlorocebus aethiops, Protein Isoforms, Genes, Tumor Suppressor, MESH: Animals, Adenosine Triphosphatases, 0303 health sciences, Mutation, Brain Neoplasms, Astrocytoma, MESH: Gene Expression Regulation, Neoplastic, MESH: Drug Resistance, Neoplasm, DNA-Binding Proteins, Gene Expression Regulation, Neoplastic, MESH: COS Cells, Cell Transformation, Neoplastic, Chromosomes, Human, Pair 1, 030220 oncology & carcinogenesis, COS Cells, MESH: Brain Neoplasms, MESH: Caco-2 Cells, MESH: Mutation, MESH: Cell Line, Tumor, MESH: Chromosomes, Human, Pair 1, Oligodendroglioma, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Biology, Diagnosis, Differential, Mitochondrial Proteins, 03 medical and health sciences, MESH: Diagnosis, Differential, Glioma, Cell Line, Tumor, MESH: Cell Proliferation, medicine, Biomarkers, Tumor, Animals, Humans, Neoplasm Invasiveness, [SDV.BC] Life Sciences [q-bio]/Cellular Biology, neoplasms, MESH: Mice, MESH: Oligodendroglioma, 030304 developmental biology, Cell Proliferation, MESH: Humans, Cell growth, Membrane Proteins, Cell Biology, MESH: Neoplasm Invasiveness, MESH: Genes, Tumor Suppressor, medicine.disease, Embryonic stem cell, Molecular biology, MESH: Cercopithecus aethiops, nervous system diseases, MESH: Hela Cells, MESH: Astrocytoma, Cell culture, Drug Resistance, Neoplasm, MESH: Cell Transformation, Neoplastic, MESH: Tumor Markers, Biological, Cancer research, NIH 3T3 Cells, ATPases Associated with Diverse Cellular Activities, Caco-2 Cells, MESH: DNA-Binding Proteins, HeLa Cells, MESH: NIH 3T3 Cells
Abstract

International audience; Human oligodendrogliomas are chemosensitive gliomas usually characterized by a loss of heterozygosity in the large distal regions of the short arm of chromosome 1 (1p LOH). Chemoresistant astrocytomas do not have this genetic signature, suggesting that the 1p arms may contain anti-oncogene and/or genes enabling chemoresistance. We have focused here on two human 1p-distal genes, ATAD 3A and ATAD 3B (1p36-33), and analyzed their gene products in normal human cell lines and tissues and in glioma-derived human cell lines. Using specific anti-peptide antibodies, we have found that ATAD 3A is ubiquitously expressed, whereas ATAD 3B is expressed in embryonic tissues, adult germinative zone and in astrocytoma cell lines but it is not expressed in oligodendroglioma cell lines or in the adult cortex. Furthermore, we have found that human glioma cell lines overexpressing or underexpressing ATAD 3A and ATAD 3B, show modified cell growth, anchorage-independent growth, and chemoresistance to doxorubicin and other genotoxic drugs. These results demonstrate the potential for ATAD 3B as a putative marker in discriminating astrocytomas from oligodendrogliomas. We also have shown that the loss of ATAD 3A/3B may be involved in the transformation pathway and the chemosensitivity of oligodendrogliomas.

Published
2008
Full Text
View/download PDF

8. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas

Author

Gaëlle Pierron, Michèle Kujas, Emmanuel Barillot, Carlo Lucchesi, Elodie Manié, Marc Sanson, Isabel Brito, Ahmed Idbaih, Karima Mokhtari, Virginie Raynal, Yannick Marie, Olivier Delattre, Véronique Mosseri, Alain Aurias, Khê Hoang-Xuan, Jean-Yves Delattre, Unité de génétique et biologie des cancers ( U830 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut Curie-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Biologie des Interactions Neurones / Glie, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Unité de Génétique Somatique, INSTITUT CURIE, Service de biostatistique ( IC10213 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -INSTITUT CURIE, Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Laboratoire de Neuropathologie Raymond Escourolle, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Service de Bioinformatique ( CURIE-BIOINFO ), Unité de génétique et biologie des cancers (U830), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie [Paris], Service de biostatistique (IC10213), Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Pierre et Marie Curie - Paris 6 (UPMC), Service de Bioinformatique (CURIE-BIOINFO), Idbaih, Ahmed, Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire de Neuropathologie Raymond Escourolle [CHU Pitié-Salpétriêre], Université Pierre et Marie Curie - Paris 6 (UPMC)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Male, Pathology, Chromosomes, Artificial, Bacterial, MESH: Chromosomes, Human, Pair 19, MESH : Aged, Loss of Heterozygosity, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Nucleic Acid Hybridization, 0302 clinical medicine, MESH : Chromosomes, Human, Pair 10, MESH: Middle Aged, Clinical pathology, Brain Neoplasms, Nucleic Acid Hybridization, Prognosis, MESH : Nucleic Acid Hybridization, 3. Good health, MESH : Chromosomes, Human, Pair 19, ErbB Receptors, Oncology, Chromosomes, Human, Pair 1, 030220 oncology & carcinogenesis, Chromosome Deletion, Chromosomes, Human, Pair 9, Chromosomes, Human, Pair 7, MESH : Chromosomes, Artificial, Bacterial, medicine.medical_specialty, MESH: Chromosomes, Artificial, Bacterial, MESH: Chromosome Deletion, Oligodendroglioma, MESH: Receptor, Epidermal Growth Factor, World Health Organization, Disease-Free Survival, MESH: Prognosis, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Humans, MESH : Middle Aged, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], MESH : Predictive Value of Tests, Pathological, Aged, [SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Humans, Proportional hazards model, MESH : Humans, MESH: Adult, medicine.disease, MESH : Proportional Hazards Models, MESH : Chromosome Deletion, Survival Analysis, MESH: Astrocytoma, MESH: Disease-Free Survival, [ SDV.GEN ] Life Sciences [q-bio]/Genetics, MESH: Female, 030217 neurology & neurosurgery, Comparative genomic hybridization, Cancer Research, MESH : Oligodendroglioma, Oligonucleotides, [SDV.GEN] Life Sciences [q-bio]/Genetics, MESH: World Health Organization, MESH : Chromosomes, Human, Pair 1, MESH: Glioma, MESH: Proportional Hazards Models, MESH : Chromosomes, Human, Pair 7, MESH: Oligonucleotides, MESH : Receptor, Epidermal Growth Factor, MESH : Chromosomes, Human, Pair 9, MESH : Female, MESH: Aged, MESH : Prognosis, Glioma, Middle Aged, MESH : Adult, Phenotype, MESH: Predictive Value of Tests, MESH: Survival Analysis, MESH: Brain Neoplasms, MESH : Disease-Free Survival, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Adult, MESH: Chromosomes, Human, Pair 7, MESH: Chromosomes, Human, Pair 1, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Oligonucleotides, Biology, Astrocytoma, Malignancy, MESH: Multivariate Analysis, Predictive Value of Tests, medicine, MESH : Brain Neoplasms, MESH: Oligodendroglioma, Proportional Hazards Models, MESH: Loss of Heterozygosity, Chromosomes, Human, Pair 10, Breakpoint, Cancer, MESH : Multivariate Analysis, MESH : Astrocytoma, MESH: Male, MESH: Chromosomes, Human, Pair 10, MESH : Glioma, [ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Multivariate Analysis, Cancer research, MESH : World Health Organization, MESH : Survival Analysis, MESH: Chromosomes, Human, Pair 9, Chromosomes, Human, Pair 19, MESH : Loss of Heterozygosity
Abstract

International audience; The pathological classification of gliomas constitutes a critical step of the clinical management of patients, yet it is frequently challenging. To assess the relationship between genetic abnormalities and clinicopathological characteristics, we have performed a genetic and clinical analysis of a series of gliomas. A total of 112 gliomas were analyzed by comparative genomic hybridization on a BAC array with a 1 megabase resolution. Altered regions were identified and correlation analysis enabled to retrieve significant associations and exclusions. Whole chromosomes (chrs) 1p and 19q losses with centromeric breakpoints and EGFR high level amplification were found to be mutually exclusive, permitting identification of 3 distinct, nonoverlapping groups of tumors with striking clinicopathological differences. Type A tumors with chrs 1p and 19q co-deletion exhibited an oligodendroglial phenotype and a longer patient survival. Type B tumors were characterized by EGFR amplification. They harbored a WHO high grade of malignancy and a short patient survival. Finally, type C tumors displayed none of the previous patterns but the presence of chr 7 gain, chr 9p deletion and/or chr 10 loss. It included astrocytic tumors in patients younger than in type B and whose prognosis was highly dependent upon the number of alterations. A multivariate analysis based on a Cox model shows that age, WHO grade and genomic type provide complementary prognostic informations. Finally, our results highlight the potential of a whole-genome analysis as an additional diagnostic in cases of unclear conventional genetic findings.

Published
2008
Full Text
View/download PDF

9. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors

Author

Soufiane El Hallani, Blandine Boisselier, Florence Laigle-Donadey, Mathieu P Rodero, Catherine Carpentier, Ahmed Idbaih, Emmanuelle Crinière, Marc Sanson, Yannick Marie, François Ducray, Khê Hoang-Xuan, Jean-Yves Delattre, Sophie Paris, Biologie des Interactions Neurones / Glie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques (LCBPT - UMR 8601), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), UPMC - Département de neurologie 2 - Mazarin, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Immunologie cellulaire et tissulaire, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Idbaih, Ahmed, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)

Subjects
Male, Cancer Research, [SDV]Life Sciences [q-bio], [SDV.GEN] Life Sciences [q-bio]/Genetics, Immunoenzyme Techniques, MESH: Glioma, MESH: Genotype, 0302 clinical medicine, Genotype, Oligodendroglial Tumor, MESH: Tumor Suppressor Protein p53, ComputingMilieux_MISCELLANEOUS, MESH: Aged, MESH: Middle Aged, MESH: Codon, Brain Neoplasms, Astrocytoma, DNA, Neoplasm, Glioma, Middle Aged, Prognosis, MESH: Case-Control Studies, Survival Rate, Chromosomes, Human, Pair 1, 030220 oncology & carcinogenesis, MESH: Brain Neoplasms, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Adult, MESH: Survival Rate, MESH: Chromosomes, Human, Pair 1, Oligodendroglioma, MESH: DNA, Neoplasm, [SDV.CAN]Life Sciences [q-bio]/Cancer, Single-nucleotide polymorphism, Biology, MESH: Prognosis, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: Polymorphism, Genetic, Genetics, medicine, Humans, SNP, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Codon, MESH: Immunoenzyme Techniques, MESH: Oligodendroglioma, Molecular Biology, Aged, [SDV.GEN]Life Sciences [q-bio]/Genetics, Polymorphism, Genetic, MESH: Humans, Case-control study, MESH: Adult, medicine.disease, Molecular biology, MESH: Male, MESH: Astrocytoma, Case-Control Studies, MESH: Microsatellite Repeats, Tumor Suppressor Protein p53, MESH: Female, 030217 neurology & neurosurgery, Microsatellite Repeats
Abstract

International audience; The functional single-nucleotide polymorphism (SNP) in codon 72 of TP53 has been shown to be both a risk factor and a prognostic biomarker in various cancers. Such results were also reported in brain tumors, notably in astrocytomas. This SNP has never been precisely investigated in oligodendroglial tumors. We retrospectively analyzed blood samples of 275 oligodendroglial tumor patients for the TP53 codon 72 polymorphism and compared them with a series of 144 healthy controls. Arg/Arg, Arg/Pro, and Pro/Pro genotypes were found in 54.2 versus 60.4%, 39.3 versus 34.0%, and 7.3 versus 5.6% of patients and controls, respectively. This suggests no association between oligodendroglial tumors and the SNP in codon 72 of TP53. Similarly, no correlation was found among the TP53 codon 72 polymorphism and prognosis, p53 expression, and chromosomes 1p and 19q status.

Published
2007
Full Text
View/download PDF

10. Perfusion-sensitive MRI of pilocytic astrocytomas: initial results

Author

Michel Peoc'h, V Lefournier, Alexandre Krainik, François Berger, Stéphane Kremer, Sylvie Grand, Stephan Chabardes, Irène Troprès, Dominique Hoffmann, C. Pasteris, Jean François Le Bas, Basile Pasquier, Département de neuro-radiologie, CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Service de neuroradiologie, CHU Strasbourg-Hôpital de Haute Pierre, RMN biomédicale : de la cellule à l'homme (RBCH), Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-DIR CENTRALE DU SSA-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de neurochirurgie, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Neurosciences précliniques, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neuropathologie, CHU Grenoble-Hôpital Michallon, CHU Saint-Etienne, and Issartel, Jean-Paul

Subjects
Gadolinium DTPA, Male, MESH: Blood Volume, Contrast Media, Perfusion scanning, MESH: Magnetic Resonance Angiography, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, Vascularity, MESH: Child, Child, Neuroradiology, Blood Volume, medicine.diagnostic_test, Pilocytic astrocytoma, Brain Neoplasms, Astrocytoma, MESH: Cerebrovascular Circulation, Cerebrovascular Circulation, MESH: Brain Neoplasms, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Radiology, medicine.symptom, Cardiology and Cardiovascular Medicine, Perfusion, Adult, medicine.medical_specialty, Adolescent, MESH: Gadolinium DTPA, 03 medical and health sciences, Glioma, MESH: Contrast Media, medicine, Humans, Radiology, Nuclear Medicine and imaging, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Retrospective Studies, MESH: Adolescent, MESH: Humans, business.industry, Magnetic resonance imaging, MESH: Adult, MESH: Retrospective Studies, medicine.disease, MESH: Male, MESH: Astrocytoma, Neurology (clinical), Nuclear medicine, business, MESH: Female, Magnetic Resonance Angiography, 030217 neurology & neurosurgery
Abstract

International audience; PURPOSE: To present the imaging and perfusion data obtained in nine patients with pilocytic astrocytomas (PA) and to discuss the original functional issues of this technique. METHOD: Nine patients with pathologically proven PA underwent conventional and perfusion MR imaging. Various areas of relative cerebral blood volume (rCBV) within the tumors were obtained. The maximum rCBV ratios were identified and considered as representative of the tumor. The results were compared with the pathological findings. RESULTS: In all patients, rCBV was

Published
2007
Full Text
View/download PDF

11. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization

Author

Frédéric Fina, Dominique Figarella-Branger, Pierre-Marie Martin, N. Baeza, Isabelle Nanni, C. Bartoli, N. Eudes, L'Houcine Ouafik, Carole Colin, Laboratoire de Biopathologie de l'Adhésion et de la Signalisation (EA3281), Université de la Méditerranée - Aix-Marseille 2, Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Rôle et mécanismes d'action de l'adrenomedulline dans la croissance tumorale : Application au modèle des gliomes, Université de la Méditerranée - Aix-Marseille 2-IFR11-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'anatomie pathologique et neuropathologique, Université de la Méditerranée - Aix-Marseille 2-CHU Marseille, Ouafik, L'Houcine, and Institut National de la Santé et de la Recherche Médicale (INSERM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Aix Marseille Université (AMU)

Subjects
Male, Cancer Research, Apolipoprotein D, MESH: RNA, Messeng, medicine.disease_cause, MESH: Nucleic Acid Hybridization, 0302 clinical medicine, Gene expression, RNA, Neoplasm, Oligonucleotide Array Sequence Analysis, Genetics, MESH: Aged, 0303 health sciences, Pilocytic astrocytoma, Brain Neoplasms, Reverse Transcriptase Polymerase Chain Reaction, MESH: Glioblastoma, Nucleic Acid Hybridization, Astrocytoma, MESH: Gene Expression Regulation, Neoplastic, Gene Expression Regulation, Neoplastic, Child, Preschool, 030220 oncology & carcinogenesis, MESH: Brain Neoplasms, Female, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, 03 medical and health sciences, MESH: Gene Expression Profiling, [SDV.CAN] Life Sciences [q-bio]/Cancer, Glioma, Biomarkers, Tumor, medicine, Humans, RNA, Messenger, Molecular Biology, MESH: Genes, Neoplasm, Aged, 030304 developmental biology, MESH: Humans, Gene Expression Profiling, MESH: Child, Preschool, medicine.disease, MESH: Male, Gene expression profiling, MESH: Astrocytoma, Suppression subtractive hybridization, Subtraction Technique, MESH: Oligonucleotide Array Sequence Analysis, Cancer research, Glioblastoma, Carcinogenesis, MESH: Female, Genes, Neoplasm
Abstract

Glioblastoma (GBM) is a highly malignant glioma, which has the propensity to infiltrate throughout the brain in contrast to pilocytic astrocytoma (PA) of the posterior fossa, which does not spread and can be cured by surgery. We have used Suppression Subtractive Hybridization to define markers that better delineate the molecular basis of brain invasion and distinguish these tumor groups. We have identified 106 genes expressed in PA versus GBM and 80 genes expressed in GBM versus PA. Subsequent analysis identified a subset of 20 transcripts showing a common differential expression pattern for the two groups. GBM differs from PA by the expression of five genes involved in invasion and angiogenesis: fibronectin, osteopontin, chitinase-3-like-1 (YKL-40), keratoepithelin and fibromodulin. PA differs from GBM by the expression of genes related to metabolism (apolipoprotein D), proteolysis (protease-serine-11), receptor and signal transduction (PLEKHB1 for Pleckstrin-Homology-domain-containing-protein-family-B-member-1), transcription/translation (eukaryotic-translation-elongation-factor-1-alpha1) processes and cell adhesion (SPOCK1 for SPARC/Osteonectin-CWCV-kazal-like-domains-proteoglycan). The expression of these genes was confirmed by real-time quantitative RT-PCR and immunohistochemistry. This study highlights the crucial role of brain invasion in GBM and identifies specific molecules involved in this process. In addition, it offers a restricted list of markers that accurately distinguish PA from GBM.

Published
2006
Full Text
View/download PDF

12. Identification of a human glial fibrillary acidic protein cDNA: A tool for the molecular analysis of reactive gliosis in the mammalian central nervous system

Author

Alain Privat, Sylviane Boularand, Jacques Mallet, Philippe Vernier, F. De Vitry, N. Faucon Biguet, P. Rataboul, Laboratoire de neurobiologie cellulaire et moléculaire (NBCM), Centre National de la Recherche Scientifique (CNRS), Neuroendocrinologie Cellulaire, Collège de France, Laboratoire de Neurobiologie du Développement INSERM, and PERIGNON, Alain

Subjects
Male, Untranslated region, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, MESH: Amino Acid Sequence, MESH: Base Sequence, Tumor Cells, Cultured, MESH: Glial Fibrillary Acidic Protein, Coding region, MESH: Animals, Gliosis, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Glial fibrillary acidic protein, MESH: Molecular Weight, MESH: DNA, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, MESH: Gliosis, GFAP stain, MESH: Rats, Inbred Strains, Substantia Nigra, medicine.anatomical_structure, Astrocyte, MESH: Hydroxydopamines, MESH: Rats, Molecular Sequence Data, MESH: Substantia Nigra, In situ hybridization, Astrocytoma, Biology, Hydroxydopamines, Cellular and Molecular Neuroscience, Glial Fibrillary Acidic Protein, medicine, Animals, Humans, MESH: Tumor Cells, Cultured, Amino Acid Sequence, RNA, Messenger, Oxidopamine, MESH: RNA, Messenger, Southern blot, MESH: Molecular Sequence Data, MESH: Humans, Base Sequence, cDNA library, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Rats, Inbred Strains, DNA, Molecular biology, MESH: Male, Rats, MESH: Oxidopamine, Molecular Weight, MESH: Astrocytoma, nervous system, biology.protein, [SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences
Abstract

International audience; Two clones encoding human glial fibrillary acidic protein (GFAP) were isolated from a human astrocytoma cDNA library. The clones pHGFAP1 and pHGFAP2 were selected by the combined use of differential colony hybridization and hybridization-selection technique with polyclonal anti GFAP antiserum. The longer one, pHGFAP1, encompasses 3.0 kb and includes the 1.8 kb long 3' untranslated region specific to the human mRNA. Sequence data disclosed an extensive homology within the coding region of human and mouse GFAP cDNAs even in the end domains. Blot hybridization analysis of RNAs from human, rat and mouse brain revealed a single GFAP mRNA species of 3.1, 2.8 and 2.7 kb respectively and Southern blot experiments indicated that this mRNA is most probably transcribed from a unique gene. In situ hybridization performed with biotinylated probes on cultured mouse brain cells suggests both the sorting and the transport of GFAP mRNA throughout the cytoplasm and processes of the astrocytes. As a model of reactive gliosis secondary to degenerative disorders, 6-hydroxydopamine (6-OHDA) lesion of the substantia nigra in the rat was performed. GFAP mRNA increased 1.4 fold in the ipsilateral striatum on day 10 after the lesion. It then declined to the control level 4 months later contrasting with the lower and more sustained increase in preproenkephalin (PPE) mRNA. The interspecies cross-reactivity of the HGFAP probes make them useful as a tool for the molecular analysis of reactive gliosis in various experimental models.

Published
1988
Full Text
View/download PDF

13. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders

Author

E.A. Cabanis, P. Grenier, M Laval-Jeantet, D. Lallemand, D. Le Bihan, E. Breton, Service NEUROSPIN (NEUROSPIN), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, IFR de Neuroimagerie Fonctionnelle (IFR 49), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), National Institutes of Health [Bethesda] (NIH), Service Hospitalier Frédéric Joliot (SHFJ), Service de Biophysique et Médecine Nucléaire, CHU Strasbourg-Université Louis Pasteur - Strasbourg I-Hôpital de Hautepierre [Strasbourg], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), division giqual, Centre national du machinisme agricole, du génie rural, des eaux et forêts (CEMAGREF), Departement de neuro-radiologie, Centre Hospitalier National d'Ophtalmologie des XV-XX, Departement de Neuroradiologie, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (CHNO), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Service de radiologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], CHU Pitié-Salpêtrière [APHP], Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Magnetic Resonance Spectroscopy, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, MESH: Brain Diseases, Astrocytoma, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Nuclear magnetic resonance, medicine, Humans, Effective diffusion coefficient, Radiology, Nuclear Medicine and imaging, Diffusion (business), Intravoxel incoherent motion, Brain Diseases, Molecular diffusion, MESH: Humans, medicine.diagnostic_test, Brain Neoplasms, business.industry, MESH: Magnetic Resonance Spectroscopy, Attenuation, MESH: Hydrocephalus, Magnetic resonance imaging, MESH: Cerebrovascular Circulation, MESH: Astrocytoma, Cerebrovascular Circulation, Restricted Diffusion, MESH: Brain Neoplasms, business, Perfusion, 030217 neurology & neurosurgery, Hydrocephalus
Abstract

International audience; Molecular diffusion and microcirculation in the capillary network result in a distribution of phases in a single voxel in the presence of magnetic field gradients. This distribution produces a spin-echo attenuation. The authors have developed a magnetic resonance (MR) method to image such intravoxel incoherent motions (IVIMs) by using appropriate gradient pulses. Images were generated at 0.5 T in a high-resolution, multisection mode. Diffusion coefficients measured on images of water and acetone phantoms were consistent with published values. Images obtained in the neurologic area from healthy subjects and patients were analyzed in terms of an apparent diffusion coefficient (ADC) incorporating the effect of all IVIMs. Differences were found between various normal and pathologic tissues. The ADC of in vivo water differed from the diffusion coefficient of pure water. Results were assessed in relation to water compartmentation in biologic tissues (restricted diffusion) and tissue perfusion. Nonuniform slow flow of cerebrospinal fluid appeared as a useful feature on IVIM images. Observation of these motions may significantly extend the diagnostic capabilities of MR imaging.

Published
1986

Catalog

Books, media, physical & digital resources
See catalog results